Abstract

BackgroundEndometrial cancer (EC) is the 8th leading cause of cancer death amongst American women. Most ECs are endometrioid, serous, or clear cell carcinomas, or an admixture of histologies. Serous and clear ECs are clinically aggressive tumors for which alternative therapeutic approaches are needed. The purpose of this study was to search for somatic mutations in the tyrosine kinome of serous and clear cell ECs, because mutated kinases can point to potential therapeutic targets.MethodsIn a mutation discovery screen, we PCR amplified and Sanger sequenced the exons encoding the catalytic domains of 86 tyrosine kinases from 24 serous, 11 clear cell, and 5 mixed histology ECs. For somatically mutated genes, we next sequenced the remaining coding exons from the 40 discovery screen tumors and sequenced all coding exons from another 72 ECs (10 clear cell, 21 serous, 41 endometrioid). We assessed the copy number of mutated kinases in this cohort of 112 tumors using quantitative real time PCR, and we used immunoblotting to measure expression of these kinases in endometrial cancer cell lines.ResultsOverall, we identified somatic mutations in TNK2 (tyrosine kinase non-receptor, 2) and DDR1 (discoidin domain receptor tyrosine kinase 1) in 5.3% (6 of 112) and 2.7% (3 of 112) of ECs. Copy number gains of TNK2 and DDR1 were identified in another 4.5% and 0.9% of 112 cases respectively. Immunoblotting confirmed TNK2 and DDR1 expression in endometrial cancer cell lines. Three of five missense mutations in TNK2 and one of two missense mutations in DDR1 are predicted to impact protein function by two or more in silico algorithms. The TNK2P761Rfs*72 frameshift mutation was recurrent in EC, and the DDR1R570Q missense mutation was recurrent across tumor types.ConclusionsThis is the first study to systematically search for mutations in the tyrosine kinome in clear cell endometrial tumors. Our findings indicate that high-frequency somatic mutations in the catalytic domains of the tyrosine kinome are rare in clear cell ECs. We uncovered ten new mutations in TNK2 and DDR1 within serous and endometrioid ECs, thus providing novel insights into the mutation spectrum of each gene in EC.Electronic supplementary materialThe online version of this article (doi:10.1186/1471-2407-14-884) contains supplementary material, which is available to authorized users.

Highlights

  • Endometrial cancer (EC) is the 8th leading cause of cancer death amongst American women

  • The Tyrosine kinase non-receptor 2 (TNK2) and Discoidin domain receptor tyrosine kinase 1 (DDR1) tyrosine kinases are somatically mutated in endometrial carcinomas In a mutation discovery screen, we sequenced 577 exons that encode the catalytic domains of 86 tyrosine kinases (Additional file 3), from 24 serous, 11 clear cell, and 5 mixed histology endometrial carcinomas

  • The somatic mutations occurred in TNK2 (Tyrosine kinase non-receptor protein 2) and DDR1 (Discoidin domain receptor tyrosine kinase 1)

Read more

Summary

Introduction

Endometrial cancer (EC) is the 8th leading cause of cancer death amongst American women. Endometrioid endometrial carcinomas (EECs) represent the vast majority of diagnosed cases [1]. They are generally estrogen-dependent tumors that are associated with a number of well-established epidemiological risk factors that lead to unopposed estrogen exposure including obesity, nulliparity, early age at menarche, and late age at menopause [2]. Serous and clear cell ECs are high-grade tumors that are rare at diagnosis but are clinically aggressive and contribute substantially to mortality from endometrial cancer (reviewed in [5]). In a large retrospective study of 5,694 cases of endometrial cancer in the US, serous and clear cell tumors together represented 13% of diagnoses but accounted for 47% of deaths [6]. Current therapeutic approaches to treat patients with serous or clear cell ECs are variable but generally include surgery and adjuvant chemotherapy and/or radiotherapy [10,11]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call